Adverse reactions -

Cardiovascular -    25%
 Vasodilation 25%  

CNS - 30%
Dizziness 5%    insomnia  5%  paresthesia  5%  depression 4% anxiety 3%

Dermatologic -   20%
Rash  6%   sweating   4%

GI -  50%
Nausea    23%   vomiting 10%   constipation 10%  diarrhea  10% anorexia  8%

GU - 16%
Urinary tract infection 5%  

Hemic/lymphatic - 11%
Anemia    4%

Metabolic/nutrional  - 16%
Peripheral edema   8%  

Musculoskeletal - 22%
Bone pain  13%    arthiritis 2%  

Respiratory - 35%
Pharyngitis   15%  dyspnea  13%  increased cough 8%  

Miscellaneous -  65%
Asthenia  20%   pain  16%  headache 14%  back pain 13%  abdominal pain 10%
injection site pain  9%  pelvic pain 8%  chest pain 6%  flu syndrome 6%  fever 5%
accidental injury   3%

Pregnany women . hypersensitivity to the drug

Special precautions/Warnings-

Child bearing women- exclude pregnancy before stating treatment with fulvestrant

Pregnancy - women of child bearing age should be adviced not  to become pregnant while
receiving fulvestarant. Fulvestarant can cause harm when adsminstrated to a pregnant woman.

Lactation- Decide whether to discontinue nursing or discontinue the drug depending on the
importance of the drug to the mother

Children- safety and efficacy have not been established

Indication-

Breast Cancer

Dosage-
Adults - 250mg administerd  intramuscularly into the buttock at intervals of 1 month as either
a single 5ml injection or concurrent 2.5ml injections . The injection should be administered slowly.

Storage - Refrigerate  2 to 8C ( 36 to 46F ) . Store in the original package.

1. Advice  women of child bearing age  not  to become pregnant while receiving fulvestarant.
  Fulvestarant can cause harm when adminstrated to a pregnant woman.

2. Your doctor may decide whether to you should discontinue nursing or the drug depending on the  importance of the drug to the mother

3. Safety and efficacy have not been established

Pregnancy -
Women of child bearing age should be adviced not  to become pregnant while
receiving fulvestrant. Fulvestrant can cause harm when adsminstrated to a pregnant woman.

Lactation-
Decide whether to discontinue nursing or discontinue the drug depending on the
importance of the drug to the mother

Children-
Safety and efficacy have not been established